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Staphylococcusaureus triggers inflammation through
inflammasome activation and recruitment of neutro-
phils, responses that are critical for pathogen clear-
ance but are associated with substantial tissue
damage. We postulated that necroptosis, cell death
mediated by the RIPK1/RIPK3/MLKL pathway, would
function to limit pathological inflammation. In models
of skin infection or sepsis, Mlkl/ mice had high
bacterial loads, an inability to limit interleukin-1b
(IL-1b) production, and excessive inflammation.
Similarly, mice treated with RIPK1 or RIPK3 inhibitors
had increased bacterial loads in a model of sepsis.
Ripk3/ mice exhibited increased staphylococcal
clearance and decreased inflammation in skin and
systemic infection, due to direct effects of RIPK3 on
IL-1b activation and apoptosis. In contrast to Casp1/
4/ mice with defective S. aureus killing, the poor
outcomes of Mlkl/ mice could not be attributed
to impaired phagocytic function. We conclude that
necroptotic cell death limits the pathological inflam-
mation induced by S. aureus.
INTRODUCTION
Staphylococcus aureus causes pyogenic infections character-
ized by a robust inflammatory response both locally and system-
ically. This inflammation must be regulated to prevent host
tissue damage. Multiple redundant proinflammatory signaling
cascades are activated by S. aureus through pathogen-associ-
atedmolecular patterns and toxins. SeveralS. aureus toxins acti-
vate the NLRP3 inflammasome and caspase-1 to generate inter-
leukin-1b (IL-1b), IL-18, and pyroptosis, a highly proinflammatory
mechanism of cell death (Craven et al., 2009; Mun˜oz-Planillo
et al., 2009). Pyroptosis, along with the generation of reactive
oxygen species (ROS) and the proteolytic activity of phagocytes,
contributes to eradication of endocytosed pathogens (Miao
et al., 2010; Sokolovska et al., 2013).Cell Re
This is an open access article under the CC BY-NThe balance between sufficient proinflammatory signaling to
clear infection and the potentially lethal consequences of inflam-
masome activation has been extensively studied in the context
of tumor necrosis factor (TNF)- and lipopolysaccharide (LPS)-
induced mortality (Aziz et al., 2014; Duprez et al., 2011; Lawlor
et al., 2015). Systemic effects of IL-1b and IL-18 are major fac-
tors in sepsis- and endotoxemia-associated mortality (Vanden
Berghe et al., 2014a). Cell death through pyroptosis can also
contribute to the control of infection, through release of endocy-
tosed pathogens that are more efficiently killed by neutrophils
(Miao et al., 2010).
Like immune cells, keratinocytes undergo caspase-1-medi-
ated pyroptosis and IL-1b production in response to S. aureus,
contributing to the eradication of skin infection (Soong et al.,
2012, 2015). Keratinocytes follow a highly regulated pattern of
proliferation, maturation, cornification, and cell death through
several mechanisms, including apoptosis and necroptosis
(Nestle et al., 2009; Vanden Berghe et al., 2014b). S. aureus
through its pore-forming toxins induces necroptosis in immune
cells (Gonza´lez-Juarbe et al., 2015; Kitur et al., 2015). Necropto-
sis results from oligomerization of MLKL (Murphy et al., 2013),
which is initiated by RIPK3-dependent phosphorylation (Cai
et al., 2014; Sun et al., 2012) and RIPK1 (Linkermann and Green,
2014). MLKL then forms a pore that leaks intracellular contents,
with a resulting inflammatory response (Kaczmarek et al., 2013).
Like caspase-1-mediated pyroptosis, necroptosis also results
in the release of intracellular contents promoting inflammation.
Necroptosis and pyroptosis share multiple effectors, with
some of these components, including caspase-8, RIPK1, and
RIPK3, contributing to the processing and activation of IL-1b
(Kaczmarek et al., 2013; Moriwaki et al., 2015; Pasparakis
and Vandenabeele, 2015). Thus, both pyroptosis and necrop-
tosis generate substantial inflammation. RIPK1/RIPK3/MLKL
signaling can be activated by Toll-like receptors (TLRs) and
TNF receptor (TNFR)- and interferon alpha/beta receptor
(IFNAR)-mediated responses, indicating the close association
between necroptosis and pathogen recognition (Chan et al.,
2015). However, the consequences of necroptosis are not
necessarily proinflammatory. Necroptosis leads to the elimina-
tion of cells that produce cytokines and inflammatory products
and the release of bacteria to be cleared by neutrophils, leadingports 16, 2219–2230, August 23, 2016 ª 2016 The Author(s). 2219
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
to an overall decrease in inflammation (Kearney et al., 2015; Ste-
phenson et al., 2016).
Exactly how necroptosis and pyroptosis function in host
defense from S. aureus infection is unclear, given that both
signaling pathways appear to have redundant effects, stimu-
lating inflammatory signaling as well as cell death (Kang et al.,
2013, 2015).
The successful control of S. aureus infection has been sug-
gested to require two major host responses: first, the rapid sup-
pression of S. aureus replication and, second, the rapid regula-
tion of the hyper-inflammatory response that ensues (Powers
et al., 2015; Stephenson et al., 2016). We postulated that pyrop-
tosis initiates clearance of staphylococci and that necroptosis
serves to eliminate cells that cause excessive inflammation.
Using models of skin infection and sepsis, we delineate how
these signaling pathways contribute to both of these compo-
nents of successful host defense.
RESULTS
MLKL Contributes to the Clearance of S. aureus from
Infected Skin
Murine models of skin infection provide the opportunity to
monitor both inflammation and bacterial killing in an in vivo
setting (Miller et al., 2006). To determine the role of necroptosis
during skin infection, we compared the responses of Mlkl/
mice, which are unable to undergo necroptosis (Murphy et al.,
2013), with wild-type (WT) mice after a subcutaneous inocula-
tion of USA300 S. aureus (Figure 1). In comparison to WT
mice, there were significantly higher bacterial counts and
more tissue damage in the Mlkl/ mice (Figures 1A–1C). We
confirmed that S. aureus infection activates necroptosis by doc-
umenting phosphorylated MLKL in infected human keratino-
cytes (Figure S1) and demonstrating that S. aureus-induced
cytotoxicity was decreased significantly by inhibitors of MLKL
(NSA) in human keratinocytes and primary cultures (Figures
1D and 1E) and by small interfering RNA (siRNA) knockdown
of MLKL (Figures 1F and 1G) in keratinocytes. Thus, the ability
of host cells to undergo necroptosis contributed to pathogen
clearance.
We next determined whether excessive inflammation was
contributing to the defective bacterial clearance exhibited
by the Mlkl/ mice. We compared the ability of these Mlkl/
mice to activate proinflammatory cytokine production and to
recruit the immune cells necessary to clear S. aureus infection.
No differences between the WT, Mlkl/ mice were observed
after 1 day of infection either in the clearance of S. aureus or
recruitment of immune cells (Figures S2A and S2B). However,
by day 5, Mlkl/ mice had significantly more neutrophils,
macrophages, and gd T cells recruited than WT mice at the
site of infection (Figures 1H–1J; Table S1). As early as 1 day
post-infection, Mlkl/ mice had increased T cell cytokine
expression (IP-10/CXCL10, Rantes, and MIG; Figure S2C; Table
S2), cytokines that mediate inflammatory damage in the skin
(McLoughlin et al., 2006). Consistent with the heightened im-
mune cell recruitment, by day 5, Mlkl/ mice had significantly
increased proinflammatory cytokines (IL-6, TNF, IL-1b, KC,
and MIP1a; Figure 1K; Table S1).2220 Cell Reports 16, 2219–2230, August 23, 2016Thehistopathological responses to infectionalsoweredifferent.
Mlkl/miceexhibited increasednecrosis andadiposity, amarker
of inflammation (Rajala and Scherer, 2003; Scha¨ffler and Scho¨l-
merich, 2010), in comparison to WT infected controls (Figure 1L).
Mlkl/mice had hyperkeratosis andmore immune cell infiltration
as compared with the WT mice (Figure 1L). As increased IL-1b
was observed inMlkl/ infections, tissue lysates were screened
for the presence of active caspase-1 (Figure 1M). Substantially
more caspase-1 p20 was found at both baseline and following
infection in Mlkl/ than in WT mice. The Mlkl/ mice displayed
increased caspase-1 activity; increased generation of proinflam-
matory cytokines, including IL-1b; and more neutrophils but
were nonetheless unable to clear S. aureus as efficiently as
the WT mice. Together, these results suggest that necroptosis
participates in the regulation of excessive inflammation that
causes tissue damage during S. aureus skin infection.
Lack of Caspases-1/4 Is Detrimental in S. aureus Skin
Infection
We wanted to understand whether caspase-1 activation is
beneficial during S. aureus skin infection. Production of IL-1b,
which is processed by caspase-1, is critical for clearance of
S. aureus from skin (Miller et al., 2006; Sokolovska et al., 2013;
Soong et al., 2012). The contribution of the inflammasome
to bacterial clearance was tested in Casp1/4/ mice infected
with S. aureus (Figure 2). The Casp1/4/ knockout mice
exhibited significantly decreased bacterial clearance and
increased lesion sizes at 5 days after infection (Figures 2A–2C).
Similar to Mlkl/ mice, Casp1/4/ mice had increased
numbers of neutrophils and gd T cells, but not macrophages,
at the site of infection (Figures 2D–2F). Unlike Mlkl/ mice,
which exhibited an increase in many proinflammatory cytokines,
Casp1/4/ mice had increased KC only and slightly, but not
significantly, less IL-1b post-infection (Figure 2G; Table S3).
Thus, caspase-1/4 activity is necessary for S. aureus clearance
and contributes substantially to the generation of IL-1b.
Pharmacological Inhibition of RIPK1 Impairs Clearance
and Increases Inflammation
To verify participation of necroptosis in staphylococcal clear-
ance, we used a pharmacological inhibitor of the RIPK1 kinase
activity necrostatin-1 s (Nec-1 s) (Degterev et al., 2008; Takaha-
shi et al., 2012), which also obviates unanticipated effects of
the germline mutation in the Mlkl/ mice. After documenting
that Nec-1 s blocked S. aureus-induced keratinocyte cell death
in vitro (Figure 3A), we treated WT mice with Nec-1 s and
monitored their response to S. aureus skin infection (Figures
3B–3D). Similar to the Mlkl/ mice, the Nec-1-s-treated mice
had significantly larger skin lesions, greater numbers of
S. aureus recovered, and greater recruitment of inflammatory
cells (Figures 3E–3G). The overall pattern of cytokine induction
suggested that Nec-1-s-treated mice had increased levels of
proinflammatory cytokines over the DMSO control (Figure 3H;
Table S4). RIPK1 inhibition was associated with increased
inflammation seen in histological sections and increased
adiposity (Figure 3I). Thus, inhibition of necroptosis by Nec-1 s
treatment or Mlkl/ deletion leads to increased inflammation
but impaired staphylococcal killing.
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Figure 1. MLKL Contributes to the Clearance of S. aureus from Infected Skin
(A–I)Mlkl/ and wild-type (WT) mice were infected subcutaneously with 23 106 CFUs/mouse of S. aureus (SA) for 5 days and the area of infection biopsied for
analysis.
(A) S. aureus colony forming units (CFUs) recovered.
(B) Representative images of mice showing skin lesions caused by S. aureus infection.
(C) Quantification of lesion sizes from (B).
(D and E) Cytotoxicity in HaCaT (C) or primary keratinocytes (HEKn; D) pretreated with 10 mM necrosulfonamide (NSA) and infected with WT S. aureus.
(F) Cytotoxicity in MLKL-deficient HaCaT infected with S. aureus for 4 hr.
(G) Immunoblot of HaCaT with MLKL knocked down by siRNA or scrambled control.
(H–J) Number of neutrophils (PMNs) (H), macrophages (Macs) (I), and gamma-delta (gd) T cells (J) on Mlkl/ and WT mice.
(K) Cytokines from S. aureus-infected WT and Mlkl/ mice (‘‘nd’’ means ‘‘not detected’’).
(L) Representative images of trichrome stain on skin biopsies of PBS or S. aureus-infected mice. The scale bars represent 100 mm.
(M) Western blot showing cleaved caspase-1 (p20), full-length caspase-1, actin, and Ponceau on skin homogenate of infected WT and Mlkl/ mice.
Each point represents amouse, and lines showmedian values. Data are represented as bar graphs with mean ±SEM. Results shown are pooled from at least two
independent experiments. *p < 0.05; **p < 0.01. See also Figures S1 and S2 and Tables S1 and S2.Ripk3/Mice Have Enhanced S. aureusClearance from
the Skin
RIPK3 is a target of RIPK1 and a major effector of necroptosis
(Christofferson et al., 2014; Vanden Berghe et al., 2014b). How-
ever, in contrast to MLKL, which functions as an effector of
necroptosis alone, RIPK3 can directly activate apoptosis and
stimulate the NLRP3 inflammasome to generate IL-1b (Newton
and Manning, 2016). After documenting that an inhibitor ofRIPK3, GSK’872, blocked S. aureus-induced cytotoxicity in
keratinocytes (Figure 4A), we wanted to understand the role
of RIPK3 during S. aureus skin infection. Using the model of
cutaneous S. aureus infection, we noted significantly improved
outcomes in the Ripk3/ mice with decreased staphylococcal
burden (Figures 4B–4D). Significantly fewer inflammatory
cells and decreased cytokine production, including IL-1b and
granulocyte colony stimulating factor (G-CSF), were observedCell Reports 16, 2219–2230, August 23, 2016 2221
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Figure 2. Lack of Caspases-1/4 Is Detrimental in S. aureus Skin Infection
Casp1/4/ and wild-type (WT) mice were infected subcutaneously with 2 3 106 CFUs/mouse of SA for 5 days and the area of infection biopsied for analysis.
(A) S. aureus CFUs recovered.
(B) Representative images of mice showing skin lesions caused by S. aureus infection.
(C) Quantification of lesion sizes from (B).
(D–F) Number of PMNs (D), Macs (E), and gd T cells (F) on Mlkl/ and WT mice.
(G) Cytokines from S. aureus-infected WT and Mlkl/ mice.
Each point represents amouse, and lines showmedian values. Data are represented as bar graphs with mean ±SEM. Results shown are pooled from at least two
independent experiments. *p < 0.05; **p < 0.01. See also Table S3.following infection, with similar baseline cytokine activity in
Ripk3/ mice compared to WT mice (Figures 4E–4H; Table
S5). In contrast to Mlkl/ mice that had increased IL-1b pro-
duction (Figure 1K), the Ripk3/ mice had significantly less
IL-1b (Figure 4H). Histopathology was notable for better preser-
vation of skin architecture in the infected Ripk3/ mice (Fig-
ure 4I). The interactions of RIPK3 with additional binding
partners were evident, as we observed less cell death due to
apoptosis, as shown by decreased annexin V staining in both
keratinocytes and immune cells in Ripk3/ skin after infection
(Figure 4J). Thus, deletion of Ripk3 inhibited excessive inflam-2222 Cell Reports 16, 2219–2230, August 23, 2016matory signaling and enhanced eradication of S. aureus from
infected skin.
Caspases-8, -3, and -7 Are Activated by S. aureus but Do
Not Contribute to Cytotoxicity
Apoptosis and necroptosis share upstream effectors, with
RIPK1-FADD-caspase-8 cascade mediating apoptosis and
RIPK1-RIPK3-MLKL pathway regulating necroptosis in the
absence of active caspase-8 (Chan et al., 2015). Caspase-8 tar-
gets the deubiquitinase CYLD, preventing RIPK1 initiation of
necroptosis (Legarda et al., 2016). S. aureus has been shown
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Figure 3. Pharmacological Blockade of Necroptosis Leads to Worse Outcome during S. aureus Skin Infection
(A) Cytotoxicity in keratinocyte cell line (HaCaT) pretreated with necrostatin-1 stable (Nec-1 s) and infected with S. aureus MOI10 for 4 hr.
(B–I) Mice were infected subcutaneously with SA and treated with 10 mg/kg Nec-1 s or DMSO control for 5 days and their skin tissues biopsied for analysis.
(B) S. aureus CFUs recovered on day 5 from Nec-1 s (N) or DMSO-treated mice are shown.
(C) Representative images of mice showing lesions on day 5 of skin infection are shown.
(D) Quantification of lesion sizes on day 5 is shown.
(E–G) Number of PMNs (E), gd T cells (F), and Macs (G) on infected area is shown.
(H) Cytokines from S. aureus-infected mice are shown.
(I) Representative images of trichrome stain on skin biopsies of PBS or S. aureus-infected mice are shown. The scale bars represent 100 mm.
Each point represents amouse, and lines showmedian values. Data are represented as bar graphs with mean ±SEM. Results shown are pooled from at least two
independent experiments. *p < 0.05; **p < 0.01. See also Figure S3 and Table S4.previously to activate caspases-8, -3, and -7 in keratinocytes
(Soong et al., 2012). Because apoptosis and necroptosis effec-
tors are intertwined and because S. aureus has the ability to
activate both mechanisms of cell death, we wanted to dissect
which of the pathways predominate during infection. We
observed that S. aureus activated caspases-8, -3, and -7 in
macrophage and keratinocyte cell lines (Figures 5A–5C). WT as
well as toxin-deficient (agrmutant) strains of S. aureus activated
caspases-3/7 to the same extent (Figure 5B). However, deletion
of caspase-8, as tested in Casp8/Ripk3/ bone-marrow-
derived macrophages (BMDMs), did not affect the overall cyto-
toxicity ofS. aureus (Figure 5D) because they still express inflam-
masome components. Similarly, pharmacological inhibitors of
the apoptosis executioners (caspases-3/7), which decreased
the activation of these caspases (Figure 5C), did not preventS. aureus-induced cytotoxicity in THP-1 cells (Figure 5E). To
document the induction of apoptosis in vivo, we demonstrated
active caspase-3 in the sloughing corneocyte layer of keratino-
cytes on S. aureus-infected murine skin (Figure 5F). S. aureus
toxins activate necroptosis (Kitur et al., 2015), as well as pyrop-
tosis (Mun˜oz-Planillo et al., 2009, 2013; Soong et al., 2012). Thus,
whereas S. aureus can induce apoptosis executioners, nonethe-
less, cytotoxicity is mediated predominantly by the components
of the inflammasome and the RIPK1/RIPK3/MLKL necroptosis
pathways.
Caspase-1 Signaling, but Not Necroptosis, Contributes
to S. aureus Killing
In vitro assays were performed to establish whether necroptosis
participates in S. aureus killing by human keratinocytes orCell Reports 16, 2219–2230, August 23, 2016 2223
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Figure 4. Ripk3/ Mice Have Improved Outcome in S. aureus Skin Infection
(A) Cytotoxicity in HaCaT pretreated with 10 mM GSK‘872 and infected with S. aureus.
(B–J) Ripk3/ and WT mice were infected subcutaneously with SA for 5 days and skin tissues biopsied for analysis.
(B) S. aureus CFUs recovered on day 5 on day of infection are shown.
(C) Representative images of mice showing lesions on day 5 of skin infection are shown.
(D) Quantification of lesion sizes on day 5 is shown.
(E–G) Number of PMNs (E), gd T cells (F), and Macs (G) on infected area is shown.
(H) Cytokines after 5 days of infection are shown.
(I) Representative images of trichrome stain on skin biopsies of S. aureus-infected mice are shown. The scale bars represent 100 mm.
(J) Number of total annexin V+ cells and number of annexin V+ immune cells (CD54+) after 5 days of infection are shown.
Each point represents amouse, and lines showmedian values. Data are represented as bar graphs with mean ±SEM. Results shown are pooled from at least two
independent experiments. *p < 0.05; **p < 0.01. See also Table S5.immune cells. A gentamicin protection assay performed using
human keratinocytes in primary culture demonstrated that con-
centrations of NSA that prevent cytotoxicity fail to inhibit
S. aureus killing in contrast to the pan-caspase inhibitor, ZVAD
(Figures 1E and 6A). Peritoneal exudate cells (PECs) from the
Ripk3/ andMlkl/mice had no defect in their ability to phago-
cytose and kill S. aureus, whereas the Casp1/4/ PECs had
significantly impaired bacterial killing ability (Figures 6B and
6C). These results were confirmed with BMDMs, demonstrating
a lack of effect of the Ripk3 or Mlkl mutation on either staphylo-
coccal killing or the generation of IL-1b, in contrast to the
significant contribution of caspase-1 in these processes (Figures
6D–6F). Lack of caspase-1 did not completely abrogate the gen-
eration of IL-1b, suggesting that multiple pathways are involved
in the production of this cytokine (Figure 6F). To determine the2224 Cell Reports 16, 2219–2230, August 23, 2016contribution of apoptosis to bacterial killing, we incubated
BMDMs from Casp8/Ripk3/ mice with S. aureus. Casp8/
Ripk3/ BMDMs had no defect in either bacterial uptake or
killing abilities (Figures 6G and 6H). Casp8/Ripk3/ BMDMs
produce more IL-1b compared toWT BMDMs (Figure 6I), poten-
tially because the lack of both necroptosis and apoptosis com-
ponents is compensated by the upregulation of the inflamma-
some products. Thus, caspase-1-mediated responses, but not
necroptosis or apoptosis, contribute to staphylococcal death
within immune cells and keratinocytes.
MLKL and Caspase-1 Enhance Survival in a Murine
Model of S. aureus Sepsis
Our results using the skin model of infection reflect participation
of RIPK1 and MLKL in staphylococcal clearance by limiting local
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Figure 5. Activation of Caspases-8, -3, and -7 by S. aureus
(A) Western blot showing caspase-8 activation in THP-1 cells after S. aureus infection.
(B) Caspases-3/7 activation in HaCaT cells pretreated with 20 mM caspase-3/7 inhibitor or DMSO for 1 hr and stimulated with WT or agr S. aureus strains for 4 hr.
(C) Caspases-3/7 activation in THP-1 cells pretreated with 20 mM caspase-3/7 inhibitor or DMSO for 1 hr and stimulated with S. aureus for 2 hr.
(D) Cytotoxicity in WT, Casp8/Ripk3/, and Mlkl/ BMDMs after S. aureus infection.
(E) Cytotoxicity in THP-1 cells treated with DMSO or caspases-3/7 inhibitor and infected with S. aureus for 2 hr.
(F) Confocal images of skin biopsies obtained from S. aureus-infectedWT andRipk3/mice and stained for pan cytokeratin (red) and cleaved caspase-3 (green,
arrow). Magnification of 2003; scale bars, 100 mm.
Each point represents amouse, and lines showmedian values. Data are represented as bar graphs with mean ±SEM. Results shown are pooled from at least two
independent experiments. *p < 0.05; **p < 0.01.inflammation. As systemic inflammation is a major factor in the
morbidity associated withS. aureus infections, we used amurine
model of bacteremia to compare bacterial clearance when nec-
roptosis is inhibited with Nec-1 s and to highlight the participa-
tion of immune cells. Significantly greater numbers of S. aureus
were recovered from the blood 24 hr after infection in the
Nec-1-s-treated mice than from controls (Figure 7A). To confirm
the results obtained with Nec-1 s, we used GSK3002963, a
potent and specific inhibitor of RIP1 kinase activity (Berger
et al., 2015), in our mouse model of sepsis. Like Nec-1-s-treated
mice, GSK3002963-treatedmice had a decreased ability to clear
S. aureus in the blood compared to mice treated with a vehicle
control (Figure 7B). Mortality studies were then performed using
theMlkl/,Ripk3/, andCasp1/4/mice in amodel of sepsis.
We predicted that theMlkl/mice, which are unable to activate
necroptosis as a mechanism to control inflammatory responses,
would have worse outcomes and observed their increased mor-
tality (with median survival of 4 days) compared to the WT mice
(Figure 7C). Although the Ripk3/ mice are also unable to acti-
vate necroptosis, their limited ability to stimulate the inflamma-
some was predicted to similarly provide protection from exces-
sive inflammation. Survival of the Ripk3/ mice was equivalent
to that of the WT mice and significantly improved as compared
to Mlkl/ mutants (Figure 7C). Casp1/4/ mice, which have astaphylococcal killing defect as well as deficient inflammasome
activation, had significantly increased mortality (median survival
of 2 days; Figure 7C). The outcomes fromS. aureus sepsis model
are consistent with those observed in the skin, in that mutations
in the necroptosis pathway associated with excessive inflamma-
tory responses are also associated with negative outcomes.
DISCUSSION
Our findings suggest that necroptosis in the setting of either
local or systemic S. aureus infection markedly contributes to
improved outcome, not by participating in bacterial death but
by limiting the damage caused by excessive inflammation. The
importance of IL-1 signaling (Miller and Cho, 2011) and the crit-
ical role of caspase-1 in S. aureus staphylococcal killing (Cohen
and Prince, 2013; Sokolovska et al., 2013) are well established.
The mechanisms in place to regulate the toxic effects of these
cytokines are less well understood. In skin and systemic models
of infection, lack of caspase-1 resulted in significantly increased
staphylococcal survival, greater neutrophil recruitment, and
increased local pathology. However, the inability to activate
necroptosis and the associated increased caspase-1 activity
and IL-1b production were also associated with excessive local
pathology and impaired staphylococcal clearance.Cell Reports 16, 2219–2230, August 23, 2016 2225
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Figure 6. Caspases-1/4 Are Necessary for S. aureus Killing by Host Cells
(A) S. aureus killing by primary keratinocytes (HEKn cells) pretreated with 10 mMNSA or 50 mMZVAD, infected with S. aureus for 2 hr, and treated with gentamicin
for 4 hr.
(B) S. aureus uptake by mouse peritoneal exudate cells (PECs) infected with S. aureus for 1 hr.
(C) S. aureus killing by PECs infected with S. aureus for 24 hr.
(D) S. aureus uptake by BMDMs from mice after infection for 1 hr.
(E) Gentamicin protection assay showing S. aureus killing by BMDMs from WT, Ripk3/, Mlkl/, and Casp1/4/ mice.
(F) IL-1b released by BMDMs from WT, Ripk3/, Mlkl/, and Casp1/4/ mice after stimulation for 4 hr with S. aureus.
(G) S. aureus uptake by Casp8/Ripk3/ (C8/R3/) BMDMs from mice after infection for 1 hr.
(H) Gentamicin protection assay showing S. aureus killing by BMDMs from WT and Casp8/Ripk3/ mice.
(I) IL-1b released by BMDMs from WT and Casp8/Ripk3/ mice after stimulation for 4 hr with S. aureus.
Data are represented as bar graphs with mean ± SEM. Results shown are pooled from at least two independent experiments. *p < 0.05.Several lines of evidence indicate a major role of necroptosis
in regulating inflammation. Germline mutations in RIPK1/3, cas-
pase-8, and FADD that interrupt the normal regulation of cell
death pathways lead to excessive skin inflammation (Dannappel
et al., 2014), even in the absence of a potent stimulus, such as2226 Cell Reports 16, 2219–2230, August 23, 2016staphylococci. Both Mlkl/ and Nec-1-s-treated mice demon-
strate increased S. aureus persistence, despite increased
phagocyte recruitment and cytokine production. Moreover,
Mlkl/ immune cells had no defect in staphylococcal killing.
These findings in the setting of common and clinically important
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**p < 0.01.infection are consistent with recent reports indicating that cell
death through necroptosis provides a major immune-suppres-
sive function by eliminating the source of cytokine production
(Kearney et al., 2015; Stephenson et al., 2016).
Components of the necroptosis cascade are shared among
the major cell death pathways and cell fates determined by the
nature of the activating stimulus and the local cytokine milieu
(Legarda et al., 2016). As we observed, caspase-8 is activated
by S. aureus, as are the executioner caspases-3/7 as well as
RIPK1/RIPK3/MLKL and caspase-1. However, the apoptosis
pathway does not participate directly in staphylococcal clear-
ance, nor does it appear to control IL-1b production, as the
Casp8/Ripk3/ BMDMs did not have impaired generation
of this cytokine, which is critical for S. aureus clearance from
skin (Abtin et al., 2014; Miller and Cho, 2011; Miller et al., 2006;
Nestle et al., 2009). The toxin-mediated cell-death pathways
necroptosis and pyroptosis drive cytotoxicity. Our data further
document that S. aureus activation of caspase-1 and IL-1b pro-
duction contributes to S. aureus killing, as well as to the patho-
logical consequences of inflammation. This is in contrast to the
major role of apoptosis in host defense from intracellular patho-
gens, such as Yersinia pestis (Weng et al., 2014), which lack the
numerous toxins expressed by S. aureus that activate necropto-
sis (Gonza´lez-Juarbe et al., 2015; Kitur et al., 2015) and inflam-
masome-mediated pyroptosis (DuMont et al., 2013; Mun˜oz-Pla-
nillo et al., 2009, 2013).
Our data also illustrate the involvement of RIPK3 in multiple
cell death and inflammatory responses activated by S. aureus.
As has been reported by other groups, we observed the effects
of RIPK3 (independently of MLKL) in stimulating apoptosis, the
NLRP3 inflammasome, and IL-1b production (Lawlor et al.,
2015; Newton and Manning, 2016; Pasparakis and Vandena-
beele, 2015). The interruption of necroptosis through deletion
of Ripk3 did not reproduce the phenotypes observed in either
the Mlkl/ or Nec-1-s-treated mice. Instead, the improvedoutcome of the Ripk3/ mice in both skin and sepsis
models was similar to our previous observations in a model of
S. aureus pneumonia (Kitur et al., 2015). Lack ofRipk3 correlated
with decreased production of IL-1b and activation of apoptosis,
which afforded protection from S. aureus-induced inflammatory
damage.
The importance of necroptosis in regulating excessive inflam-
matory signaling was also evident in a model of sepsis. In the
absence of Mlkl, lethality occurred at a rate significantly greater
than in the WT mice, in which the immunoregulatory functions of
necroptosis remained intact. Nec-1 s treatment similarly resulted
in significantly increased rates of bacteremia early in infection,
despite a lack of impairment of S. aureus killing by cells unable
to undergo necroptosis. The sepsis model also provided the
opportunity to observe the importance of caspase-1/4 and its
participation in staphylococcal clearance, particularly at the
early stages of infection. This was in contrast to the conse-
quences of Mlkl deletion that were more apparent over time.
Our findings add to a growing body of literature demonstrating
that excessive inflammatory signaling contributes significantly to
the morbidity and mortality caused by S. aureus, both systemi-
cally and at a local site, such as the skin (Kitur et al., 2015; M€uller
et al., 2015). Our results show that the induction of necroptosis
during S. aureus infection is an essential component of the
host response necessary to limit inflammation. Targeting this
pathway or identifying mutations that are associated with its
function may provide therapeutic strategies to improve outcome
from this common cause of infection.
EXPERIMENTAL PROCEDURES
Bacteria
S. aureus strain MRSA USA300 LAC was grown overnight in Luria broth (LB)
at 37C as previously described (Kitur et al., 2015) and suspended in PBS
to achieve the required concentration. S. aureus was heat killed at 65C for
90 min.Cell Reports 16, 2219–2230, August 23, 2016 2227
Cell Culture
PECs were collected from mice that had been infected intraperitoneally with
107 colony-forming units (CFUs) of heat-killed S. aureus for 48 hr and 24 hr
(Reyes-Robles et al., 2013). S. aureus MOI 10 was opsonized for 30 min with
50% normal mouse serum (NMS) (Innovative Research) in RPMI 1640 medium
(GIBCO), washed, and suspended inmedium. PECswere infectedwith opson-
ized S. aureusMOI 1 in coated plates for 1 hr and 24 hr. PECs were lysed with
0.1% saponin and recovered bacteria (CFU) enumerated by serial dilutions.
Gentamicin protection assays were performed in HaCaT or BMDMs isolated
from mice and differentiated in the presence of 60 ng/ml of mouse M-CSF
(Peprotech). After stimulation of HaCaTs for 2 hr or BMDMs for 20 min
with S. aureus MOI 100, cells were washed and treated with gentamicin
(500 mg/ml) for 1 hr or 24 hr. Cells were washed in PBS, lysed with 0.1%
saponin, and bacteria enumerated by serial dilution on agar plates.
Cytotoxicity Assays
HaCaT and HEKn cells were grown to confluence in DMEM (GIBCO) and
THP-1 cells in RPMI 1640 medium (GIBCO) with 10% fetal bovine serum
and 1% penicillin and streptomycin at 37C and 5% CO2 in a humidified envi-
ronment. Cells weremaintained in no antibiotic medium 24 hr prior to infection.
Cells were pretreated 1 hr prior to infection with Nec-1 s (Enzo Life Technolo-
gies), 10 mM necrosulfonamide (NSA) (Calbiochem), 10 mM GSK’872 (Calbio-
chem), 20 mM caspase-3/7 inhibitor (Promega), or DMSO control (v/v). For
siRNA knockdown, HaCaT was grown to confluence and transfected with
100 nM siMLKL (human MLKL siRNA pools of three targets; Santa Cruz
Biotechnology) or scrambled siRNA control pool using Lipofectamine
RNAiMAX (Life Technologies) as previously described (Kitur et al., 2015). Cells
were infected after 3 days of siRNA treatment. S. aureusMOI 10 was added to
the cells for 4 hr for keratinocytes and 2 hr for macrophages. Lysates were
used for immunoblotting and caspases-3/7 activation assays and superna-
tants for cytotoxicity assays. Lactate dehydrogenase (LDH) cytotoxicity
was performed as per manufacturer’s instructions (Roche) and as described
previously (Kitur et al., 2015). Caspases-3/7 activation was performed as per
manufacturer’s instructions (Caspase-Glo; Promega).
Model of Skin Infection
Six- to eight-week-old sex-matched WT C57BL/6J (Jackson Laboratory),
Casp1/4/ (B6N.129S2-Casp1tm1Flv/J; Jackson Laboratory; Kuida et al.,
1995), Ripk3/ (Vishva Dixit; Genentech; Newton et al., 2004), and Mlkl/
(John Silke; WEHI via Douglas R. Green; St. Jude Children’s Research Hospi-
tal; Murphy et al., 2013) were used. Knockouts were backcrossed to C57BL/6J
background, and equal sex ratios were used for experiments. Mice were anes-
thetized, shaved, and inoculated subcutaneously on the back with 2 3 106
CFUs/mouse of S. aureus in 100 ml of PBS or with 100 ml PBS (control group)
using 265/8G sterile needle. Lesions were measured daily, and mice were
sacrificed 1 day or 5 days after infection.
Two 3-mm punch biopsy (Premier Uni-Punch) skin specimens were ob-
tained from the lesions of infected mice, and half of the tissue was fixed in
4% paraffin for 1 day and stored in 70% ethanol for histology, performed by
the Histology Core at Columbia University Medical Center. Trichrome staining
was done, and images were taken on Zeiss Axiocam MRc 5 (Zeiss).
The other half of the specimens was homogenized using a cell strainer to
obtain single-cell suspension in 400 ml PBS. Recovered bacteria were enumer-
ated by serial dilutions. Cells were spun down and homogenate used for ELISA
and cells stained for fluorescence-activated cell sorting (FACS) as described
below.
Model of Sepsis
13 108 CFUs of S. aureus in 100 ml PBS were delivered intravenously through
the retro-orbital injection route to 6- to 8-week-old anesthetized mice and
survival monitored daily. For Nec-1 s sepsis experiments, mice were treated
with 10 mg/kg Nec-1 s or DMSO control 24 hr prior, during infection, and
4 hr (for 24-hr infection) or 24 hr (for 48-hr infection) after S. aureus infection.
For GSK3002963 sepsis experiments, mice were treated with 10 mg/kg
GSK3002963 reconstituted with 10% DMSO v/v and 20% ethanol v/v in
PBS (or reconstitution solution for vehicle control) during infection and 4 hr af-
ter S. aureus infection. Mice were sacrificed 24 hr or 48 hr after infection and2228 Cell Reports 16, 2219–2230, August 23, 2016bacteria in blood enumerated and cytokines in blood analyzed as described
below.
FACS Analysis
Homogenized cells were prepared as previously detailed (Kitur et al., 2015).
Combinations of phycoerythrin (PE) anti-CD54 (YN1/1.7.4; Biolegend), fluores-
cein isothiocyanate-labeled (FITC) anti-Ly-6G (Gr-1; RB6-8C5; Biolegend),
peridinin chlorophyll (PerCP)-Cy5.5-labeled anti-CD11c (N418; Biolegend),
allophycocyanin (APC)-labeled anti-MHC II (I-A/I-E; Biolegend), and APC-
labeled anti-TCR gd T cells (gd T cells) were used. Neutrophils (PMNs)
(Ly6G+/MHCII), macrophages (Macs) (CD11C+/MHCIIlow-mid), and gd T cells
were enumerated using FlowJo V10.
Cytokine Analysis
Eve Technologies performed Multiplex ELISA on skin homogenate to deter-
mine mouse cytokine levels. Only cytokines that induced by infection are
shown. IL-1b ELISA immunoblotting was performed as previously described
(Kitur et al., 2015).
Immunoblotting and Immunohistochemistry
Cells were lysed using radioimmunoprecipitation (RIPA) buffer as previously
described (Kitur et al., 2015). Immuno-detection was done using anti-cas-
pase-1 (p20) (Casper-1; Adipogen), anti-MLKL (Abcam), anti-caspase-8 (Cell
Signaling Technology), and b-actin (Sigma-Aldrich) followed by secondary
antibodies conjugated to horseradish peroxidase (Santa Cruz Biotechnology).
Equal loading was confirmed by staining with 0.1% Ponceau S (w/v) in 5%
acetic acid (Sigma-Aldrich).
For immunohistochemistry, sections were stained with cleaved caspase-3
(Cell Signal) and anti-pan cytokeratin (Santa Cruz Biotechnology) followed
by peroxidase staining using the Immunocruz ABC Staining kit (Santa
Cruz Biotechnology). Control sections were stained with secondary antibodies
only.
Ethics Statement
Animal experiments were carried out in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals of the NIH, the
Animal Welfare Act, and US federal law. The Institutional Animal Care and Use
Committee of Columbia University approved the protocol (AC-AAAH2350 and
AC-AAAG7408).
Statistical Analysis
Samples without normal distribution were analyzed using the nonparametric
Mann-Whitney test and mouse survival analyzed by log rank (Mantel-Cox)
test for comparison of survival curves. Samples with normal distribution
were analyzed with two-tailed Student’s t test and one-way ANOVA
followed by Bonferroni corrections to correct for multiple comparisons.
p < 0.05 between groups were considered significant. Outliers were
determined by Grubb’s test and removed. Statistical analysis was per-
formed using GraphPad Prism Version 4.00 (GraphPad). Data are presented
as single points with lines representing median values or as bar graphs with
mean ± SEM.
For more experimental procedures, see the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.07.039.
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